Catalyst
Slingshot members are tracking this event:
Actinium Pharma (ATNM) Receives Guidance from European Medicines Agency Regarding Phase 3 SIERRA Study Evaluating Iomab-B in Acute Myeloid Leukemia
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ATNM |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 21, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Guidance, European Medicine's Agency, Ema, Phase 3, Sierra, Iomab-b, Acute Myeloid Leukemia
